Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-11
2005-01-11
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000, C546S123000, C546S113000, C544S362000, C544S061000, C514S253030, C514S228200
Reexamination Certificate
active
06841558
ABSTRACT:
Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating, or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
REFERENCES:
patent: 3945995 (1976-03-01), Yamada et al.
patent: 4416884 (1983-11-01), Ishikawa et al.
patent: 4996213 (1991-02-01), Mendes et al.
patent: 5294620 (1994-03-01), Ratcliffe et al.
patent: 5753666 (1998-05-01), Beasley et al.
patent: 5945431 (1999-08-01), Jin et al.
patent: 6143760 (2000-11-01), Albaugh et al.
patent: 6211376 (2001-04-01), Romines et al.
patent: 6262055 (2001-07-01), Young et al.
patent: 6294547 (2001-09-01), Oka et al.
patent: 6306891 (2001-10-01), Selnick et al.
patent: 6380249 (2002-04-01), Young et al.
patent: 6525042 (2003-02-01), Kobayashi et al.
patent: WO 9625399 (1996-08-01), None
patent: WO 9811073 (1998-03-01), None
patent: WO 9813350 (1998-04-01), None
patent: WO 9910347 (1999-03-01), None
patent: WO 9932450 (1999-07-01), None
patent: WO 0100578 (2001-01-01), None
patent: WO 0204443 (2002-01-01), None
patent: WO 0206246 (2002-01-01), None
patent: WO 03035076 (2003-05-01), None
patent: WO 03035077 (2003-05-01), None
J. Bedard et al., “Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity Against Human Cytomegalovirus”, 2000, pp. 929-937, vol. 44, Antimicrobial Agents and Chemotherapy.
Y. Pommier et al., “Retroviral Intergrase Inhibitors Year 2000: Update and Perspectives”, 2000, pp. 532-565, vol. 47, Antiviral Research.
E. Dc Clercq et al., “New Anti-HIV Agents and Targets”, 2002, pp. .531-565, vol. 22, Medicinal Research Reviews.
F. Zouhiri et al., “Structure-Activity Relationships and Binding Mode of Styrylquinolines as Potent Inhibitors of HIV-1 Integrase and Replication of HIV-1 in Cell Culture”, 2000, pp. 1533-1540, vol.. 43, J. Med. Chem.
A.L. Parrill, “HIV-1 Integrase Inhibition: Binding Sites, Structure, Activity, Relationships and Future Perspectives”, 2003, Medline Accession No. 2003338948, (Abstract of Current Med. Chem., vol. 10, No. 18, pp. 1811-1824).
L. Ratner et al., “Complete Nucleotide Sequence of the AIDS virus, HTLV III”, 1985, Nature, vol. 313, pp. 277-284.
H. Toh et al., “Close Structural Resemblance Between Putative Polymerase of a Drosophila Transposable Genetic Element 17.6 and Pol Gene Product of Moloney Murine Leukaemia Virus”, 1985, The EMBO Journal, vol. 4, No. 5, pp. 1267-1272.
M.D. Power et al., “Nucleotide Sequence of SRV-1, Type D Simian Acquired Immune Deficiency Syndrome Retrovirus”, 1986, Science, vol. 231, pp. 1567-1572.
L.H. Pearl et al., “A Structural Model for the Retroviral Process”, 1987, Nature, vol. 329, pp. 351-354.
L. Chan et al., “Discovery of 1,6-Naphthyridines as a Novel Class of Potent and Selective Human Cytomegalovirus Inhibitors”, 1999, J. Med. Chem., vol. 42, No. 16, pp. 3023-3025.
M. Ouali et al., “Modeling of the Inhibition of Retroviral Intergrases by Styrylquinoline Derivatives”, 2000, J. Med. Chem., vol. 43, pp. 1949-1957.
Derwent Abstract No. 97-048296/05, 1997 (Abstract of JP 08301849-A, Takeda Chem. Ind. Ltd., “New Heterocyclic Carboxamide Derivs.-Useful in Pharmaceuticals as Tachykinin Receptor Inhibitors”).
Chemical Abstracts No. 33-2525, 1938 (Abstract of Otiai et al., “Synthesis of 2.5 Naphthyridine Derivatives, II”, J. Pharm. Soc. Japan, vol. 58, pp. 764-770).
CAPLUS Accession No. 2001:923611, 2001, Kiyama et al., (Abstract of WO 01/95905, Assignee: Shionogi & Co., Ltd.,“Dual Divalent Metal Ion Chelators as HIV Intergrase Inhibitors”).
Derwent Abstract No. 2002-732783,2000 (Abstract of WO 02/070491, Fuji M., “New Nitrogenous Heteroaromatic Compounds are HIV Integrase Inhibitors for Treating HIV Infections, AIDS and AIDS Related Diseases”.
IPDL Abstract of WO 02/070486, Shionogi & Co., Ltd., Fuji et al., “Nitrogen- Containing Heteroaryl Compounds Having HIV Integrase Inhibitory Activity”).
Anthony Neville J.
Bennett Jennifer J.
Gomez Robert P.
Young Steven D.
Aulakh Charanjit S.
Camara Valerie J.
Merck & Co. , Inc.
Walton Kenneth R.
LandOfFree
Aza-and polyaza-naphthalenyl carboxamides useful as HIV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aza-and polyaza-naphthalenyl carboxamides useful as HIV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza-and polyaza-naphthalenyl carboxamides useful as HIV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398528